Thursday, November 21, 2019 9:13:08 AM
Regarding "I can honestly say that the Krill People, ACST, are liars and their lying goes back many years..."
FWIW....I did a little DD into the people behind the early research work done at Acasti/Neptune. It looks like JSS Medical Research Inc (which is listed on clinicaltrials.org as sponsor of the company’s 2 phase II trials) is a CRO that was founded by Dr. John S. Sampalis, a Professor of Surgery and Epidemiology & Biostatistics in the Faculty of Medicine of McGill University and the University of Montreal. He is the brother of Acasti/Neptune’s Dr. Tina Sampalis, (she received an MD in Oncology in Greece and then a PhD in Epidemiology and Experimental Surgery at McGill) who holds the key patents in her name, and in turn was a lead researcher (with Ruxandra Bunea as PI on one of the studies) on Acasti/Neptune’s 2003/2004 publications. Ruxandra Bunea was an Assistant Professor in the Department of Internal Medicine at McGill University at the time.
Of these three, John Sampalis has a current regular established research publication record (PubMed shows 114 citations but topically they are all over the place which suggests his coauthorship on these papers is related to his biostatistics expertise). Tina Sampalis (=Fotini Sampalis) has 14 citations involving mostly breast cancer research but nothing is cited after 2008. Ruxandra Bunea herself has only the two early Neptune Krill Oil publications for which I provide the links below.
http://archive.foundationalmedicinereview.com/publications/8/2/171.pdf
http://archive.foundationalmedicinereview.com/publications/9/4/420.pdf
FWIW....I did a little DD into the people behind the early research work done at Acasti/Neptune. It looks like JSS Medical Research Inc (which is listed on clinicaltrials.org as sponsor of the company’s 2 phase II trials) is a CRO that was founded by Dr. John S. Sampalis, a Professor of Surgery and Epidemiology & Biostatistics in the Faculty of Medicine of McGill University and the University of Montreal. He is the brother of Acasti/Neptune’s Dr. Tina Sampalis, (she received an MD in Oncology in Greece and then a PhD in Epidemiology and Experimental Surgery at McGill) who holds the key patents in her name, and in turn was a lead researcher (with Ruxandra Bunea as PI on one of the studies) on Acasti/Neptune’s 2003/2004 publications. Ruxandra Bunea was an Assistant Professor in the Department of Internal Medicine at McGill University at the time.
Of these three, John Sampalis has a current regular established research publication record (PubMed shows 114 citations but topically they are all over the place which suggests his coauthorship on these papers is related to his biostatistics expertise). Tina Sampalis (=Fotini Sampalis) has 14 citations involving mostly breast cancer research but nothing is cited after 2008. Ruxandra Bunea herself has only the two early Neptune Krill Oil publications for which I provide the links below.
http://archive.foundationalmedicinereview.com/publications/8/2/171.pdf
http://archive.foundationalmedicinereview.com/publications/9/4/420.pdf
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
